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ORIGINAL ARTICLE INFECTIOUS DISEASESDevelopment of two real-time multiplex PCR assays for the detection and
quantiﬁcation of eight key bacterial pathogens in lower respiratory tract
infectionsN. J. Gadsby1, M. P. McHugh1, C. D. Russell1, H. Mark1, A. Conway Morris2, I. F. Laurenson1, A. T. Hill3 and K. E. Templeton1
1) Medical Microbiology, Department of Laboratory Medicine, Royal Inﬁrmary of Edinburgh, Edinburgh, 2) Department of Anaesthesia, University of Cambridge,
Cambridge Biomedical Campus, Cambridge and 3) Respiratory Medicine, Royal Inﬁrmary of Edinburgh, Edinburgh, UKAbstractThe frequent lack of a positive and timely microbiological diagnosis in patients with lower respiratory tract infection (LRTI) is an important
obstacle to antimicrobial stewardship. Patients are typically prescribed broad-spectrum empirical antibiotics while microbiology results are
awaited, but, because these are often slow, negative, or inconclusive, de-escalation to narrow-spectrum agents rarely occurs in clinical
practice. The aim of this study was to develop and evaluate two multiplex real-time PCR assays for the sensitive detection and accurate
quantiﬁcation of Streptococcus pneumoniae, Haemophilus inﬂuenzae, Staphylococcus aureus, Moraxella catarrhalis, Escherichia coli, Klebsiella
pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. We found that all eight bacterial targets could be reliably quantiﬁed
from sputum specimens down to a concentration of 100 CFUs/reaction (8333 CFUs/mL). Furthermore, all 249 positive control isolates
were correctly detected with our assay, demonstrating effectiveness on both reference strains and local clinical isolates. The speciﬁcity
was 98% on a panel of nearly 100 negative control isolates. Bacterial load was quantiﬁed accurately when three bacterial targets were
present in mixtures of varying concentrations, mimicking likely clinical scenarios in LRTI. Concordance with culture was 100% for
culture-positive sputum specimens, and 90% for bronchoalveolar lavage ﬂuid specimens, and additional culture-negative bacterial
infections were detected and quantiﬁed. In conclusion, a quantitative molecular test for eight key bacterial causes of LRTI has the
potential to provide a more sensitive decision-making tool, closer to the time-point of patient admission than current standard methods.
This should facilitate de-escalation from broad-spectrum to narrow-spectrum antibiotics, substantially improving patient management and
supporting efforts to curtail inappropriate antibiotic use.
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p://dx.doi.org/10.1016/j.cmi.2015.05.004infection (LRTI) is an important obstacle to antimicrobial
stewardship. Patients are typically prescribed broad-spectrum
empirical antibiotics while microbiology results are awaited,
but, because these are often slow, negative, or inconclusive, de-
escalation to narrow-spectrum agents rarely occurs in clinical
practice.
Current standard diagnostic methods for respiratory bac-
teria are culture-based and typically take 24–72 h [1]. Culture
also has low sensitivity; a positive microbiological diagnosis may
only be made in approximately 30% of patients with
community-acquired pneumonia [2]. As a wide range ofEuropean Society of Clinical Microbiology and Infectious Diseases
nses/by-nc-nd/4.0/)
CMI Gadsby et al. Quantitative PCR for eight respiratory bacterial pathogens 788.e2pathogens can cause LRTI, it is common to request a mixture of
different diagnostic tests, including culture, antigen testing, and
serology, on a number of different specimen types [3]. In
contrast, the routine use of viral multiplex real-time PCR
(mRT-PCR) assays allows a single respiratory specimen to be
screened for a large number of respiratory viruses easily within
the working day [4].
We sought to improve the sensitivity and turn-around time
of microbiological diagnosis of LRTI in our centre by developing
a quantitative bacterial mRT-PCR approach. At the same time,
we wanted to simplify the process by testing the same LRT
specimen extract used for viral mRT-PCR and using the same
PCR platforms, thus ﬁtting in with our current workﬂow and
minimizing costs. A key requirement was the ability to deter-
mine the bacterial load in order to provide information that
may be clinically useful in excluding LRT specimen contamina-
tion with oral commensal bacteria.
Real-time PCR assays for some common respiratory bacteria
have been described, but no single assay covers the wide range of
Gram-positive and Gram-negative pathogens required for LRTI
diagnosis. Furthermore, some assays have a lack of sensitivity
and/or speciﬁcity for organisms such as Streptococcus pneumoniae
and Haemophilus inﬂuenzae, owing to the use of suboptimal gene
targets [3,5–10]. Several molecular respiratory pathogen panels
are currently commercially available or in development. Typi-
cally, these are more expensive than PCRs developed in-house,
lack a full range of viral and bacterial targets, are non-
quantitative, or require speciﬁc testing platforms [11–13].
The aim of this study was to develop and evaluate two mRT-
PCR assays for the sensitive detection and accurate quantiﬁ-
cation of the following eight respiratory bacterial pathogens: S.
pneumoniae, H. inﬂuenzae, Staphylococcus aureus, and Moraxella
catarrhalis (mRT-PCR 1), and Escherichia coli, Klebsiella pneu-
moniae, Pseudomonas aeruginosa, and Acinetobacter baumannii
(mRT-PCR 2).Materials and methodsPositive and negative control isolates
The positive control bacterial strains used in assay validation
were as follows: S. pneumoniae American Type Culture Collec-
tion (ATCC) 49619, H. inﬂuenzae ATCC 9007, Staphylococcus
aureus ATCC 29213, M. catarrhalis local laboratory reference
strain, E. coli ATCC 35218, K. pneumoniaeNational Collection of
Type Cultures (NCTC) 13442, P. aeruginosa ATCC 27853, and
A. baumannii NCTC 13424. Phocine herpes virus (PhHV) was
obtained as a viral cell culture stock from the Department of
Virology, University Hospital Rotterdam, for use as an internal
control. Plasmids containing assay target genes were generatedClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of Eu
This is an open access artiby cloning PCR products with the pGEM-T Easy vector system
(Promega, Southampton, UK). Plasmid extracts were diluted in
carrier polyARNA (Qiagen,Manchester, UK) at 0.05mg/L in ten-
fold dilution series for use in PCR optimization and as quantiﬁ-
cation standards. A large panel of control isolates were selected
to include organisms targeted by themRT-PCR1 andmRT-PCR2
assays, and 88 isolates closely related to the target organisms and/
or commonly found in the respiratory tract as pathogens or
commensals (Table 1). Isolates were obtained from the Royal
Inﬁrmary of Edinburgh Clinical Microbiology Laboratory, Scot-
tish Haemophilus, Legionella, Meningococcus and Pneumococcus
Reference Laboratory, Scottish MRSA Reference Laboratory,
Scottish Bacterial Sexually Transmitted Infection Reference
Laboratory, ATCC and NCTC Public Health England. Chlamy-
dophila pneumoniae and Chlamydophila psittaciwere commercially
supplied as DNA extracts (Vircell, Granada, Spain). Well-
characterized clinical isolates were from respiratory specimens
wherever possible, and were identiﬁed by colonial morphology,
standard biochemical methods, VITEK-2 (bioMérieux, Basing-
stoke, UK), Microﬂexmatrix-assisted laser desorption ionization
time-of-ﬂight mass spectrometry (Bruker, Coventry, UK), and
sequencing, as appropriate.
Nucleic acid extraction
Pure cultures of control bacterial isolates were suspended in
saline to 0.5 McFarland standard concentration, and total nucleic
acid was extracted with the DNeasy Blood and Tissue kit
(Qiagen), following the protocol for Gram-positive bacteria
according to the manufacturer’s instructions. Crude cell lysates
were also made by boiling 150 μL of cell suspension for 10 min,
centrifuging for 1 min at 11 000 g, and removing the supernatant
for testing. Sputum specimens were initially centrifuged to pellet
purulent material, and then physically homogenized in sterile
viral transport mediumwith sterile glass beads. Total nucleic acid
was extracted from 200 μL of clinical specimen with the
following protocol: 60 min of incubation with 4 μL of enzymatic
lysis buffer (20 mM Tris, pH 8, 2 mM EDTA, 1.2% Triton X-
100) + 2 μL of lysozyme (100 mg/mL) at 37°C, 60 min of incu-
bation with 25 μL of proteinase K (Qiagen) at 56°C, nucliSENS
easyMAG (bioMérieux) automated extraction with PhHV in-
ternal control added to the lysis buffer, and elution in 100 μL.
Assay design
Candidate assay targets for the eight bacteria of interest were
chosen on the basis of published validation data. The National
Centre for Biotechnology Information standard nucleotide
Basic Local Alignment Search Tool was used to check candidate
oligonucleotide sequence matches to targets in the GenBank
database. Assays were then redesigned or modiﬁed with Bea-
con Designer (Premier Biosoft, Palo Alto, CA, USA) andropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 788.e1–788.e13
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
TABLE 1. Speciﬁcity panel
Organism No. Source/strain
Positive control isolates
Streptococcus pneumoniae 36 Clinical isolates (25); SHLMPRL isolates
(10); ATCC 49619
Haemophilus inﬂuenzae 47 Clinical isolates (25); SHLMPRL isolates
(18) (serotypes A, B, D, E, F, NTHi);
ATCC 9007 (serotype C); ATCC
49766 (NTHi); ATCC 49247 (NTHi);
NCTC 8468
Staphyloccoccus aureus 41 Clinical isolates (25); SMRSARL isolates
(10); MRSA S113; ATCC 25923;
ATCC 1026; ATCC BAA-976; ATCC
BAA-977; ATCC 29213
Moraxella catarrhalis 26 Clinical isolates (25); NCTC 11020
Escherichia coli 28 Clinical isolates (25); NCTC 13476;
ATCC 25922; ATCC 35218
Klebsiella pneumoniae 28 Clinical isolates (25); NCTC 13442;
NCTC 13443; NCTC 13439
Pseudomonas aeruginosa 26 Clinical isolates (25); ATCC 27853
Acinetobacter baumannii 17 Clinical isolates (16); NCTC 13424
Negative control isolates (n = 88)
Abiotrophia adiacens 1 NCTC 13000
Acinetobacter calcoaceticus 1 Clinical isolate
Acinetobacter haemolyticus 1 NCTC 12155
Acinetobacter. johnsonii 1 NCTC 12154
Acinetobacter junii 1 NCTC 12153
Acinetobacter lwofﬁi 1 Clinical isolate
Acinetobacter nosocomialis 1 Clinical isolate
Actinomyces israelii 1 Clinical isolate
Aggregatibacter
actinomycetemcomitans
1 NCTC 9710
Aggregatibacter segnis 1 SHLMPRL isolate
Arcanobacterium haemolyticum 1 Clinical isolate
Bordetella parapertussis 1 NCTC 5952
Bordetella pertussis 1 NEQAS 1505
Chlamydophila pneumoniae
(DNA)
1 CM-1 (VR1360)
Chlamydophila psittaci (DNA) 1 6BC
Corynebacterium striatum 1 NCTC 764
Eikenella corrodens 1 ATCC BAA-1152
Enterobacter hormacecei 1 ATCC 700323
Enterococcus casseliﬂavus 1 ATCC 700327
Enterococcus faecalis 1 ATCC 51299
Fusobacerium necrophorum 1 Clinical isolate
Gemella morbillorum 1 Clinical isolate
Haemophilus aphrophilus 1 Clinical isolate
Haemophilus haemolyticus 1 NCTC 10659
Haemophilus parahaemolyticus 1 Clinical isolate
Haemophilus parainﬂuenzae 10 Clinical isolate
Haemophilus
paraphrohaemolyticus
1 NCTC 10670
Kingella kingae 1 NCTC 10529
Klebsiella oxytoca 1 Clinical isolate
Legionella pneumophila 1 Clinical isolate
Micrococcus luteus 1 Clinical isolate
Moraxella atlantae 1 NCTC 11091
Moraxella lacunata 1 NCTC 11011
Moraxella nonliquefaciens 1 NCTC 10464
Moraxella osloensis 1 Clinical isolate
Mycoplasma pneumoniae 1 NCTC 10119
Mycoplasma salivarium 1 NCTC 10113
Neisseria cinerea 1 SBSTIRL isolate
Neisseria gonorrhoeae 1 SBSTIRL isolate
Neisseria lactamica 1 SBSTIRL isolate
Neisseria meningitidis 1 SBSTIRL isolate
Neisseria mucosa 1 SBSTIRL isolate
Neisseria perﬂava 1 SBSTIRL isolate
Neisseria sicca 1 SBSTIRL isolate
Neisseria subﬂava 1 SBSTIRL isolate
Peptostreptococcus magnus 1 Clinical isolate
Porphyromonas gingivalis 1 NCTC 11834
Prevotella intermedia 1 NCTC 13070
Pseudomonas ﬂuorescens 1 NCTC 10038
Pseudomonas putida 1 NCTC 10936
Pseudomonas stutzeri 1 NCTC 10475
Staphylococcus capitis 1 SMRSARL isolate
Staphylococcus epidermidis 3 ATCC 12228, SMRSARL isolate (2)
Staphylococcus haemolyticus 2 SMRSARL isolate
Staphylococcus hominis 1 SMRSARL isolate
Staphylococcus intermedius 1 SMRSARL isolate
Staphylococcus lugdunensis 1 SMRSARL isolate
Staphylococcus
pseudintermedius
1 SMRSARL isolate
Staphylococcus saphrophyticus 1 Clinical isolate
Staphylococcus warneri 1 SMRSARL isolate
Stenotrophomonas maltophila 1 ATCC 17666
Streptococcus agalactiae 1 Clinical isolate
Streptococcus anginosus 1 Clinical isolate
TABLE 1. Continued
Organism No. Source/strain
Streptococcus bovis 1 NCTC 8177
Streptococcus constellatus 1 Clinical isolate
Streptococcus gordonii 1 Clinical isolate
Streptococcus intermedius 1 Clinical isolate
Streptococcus mitis 1 SHLMPRL isolate
Streptococcus mutans 1 Clinical isolate
Streptococcus oralis 1 Clinical isolate
Streptococcus parasanguinis 2 SHLMPRL isolate, clinical isolate
Streptococcus pyogenes 1 Clinical isolate
Streptococcus salivarius 1 ATCC 19258
Streptococcus sanguinis 1 Clinical isolate
Ureaplasma urealyticum 1 NCTC 10177
ATCC, American Type Culture Collection; MRSA, methicillin-resistant
Staphylococcus aureus; NCTC, National Collection of Type Cultures, Public Health
England; NTHi, non-typeable Haemophilus inﬂuenzae; SBSTIRL, Scottish Bacterial
Sexually Transmitted Infection Reference Laboratory; SHLMPRL, Scottish
Haemophilus, Legionella, Meningococcus and Pneumococcus Reference Laboratory;
SMRSARL, Scottish MRSA Reference Laboratory.
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mance. Optimized oligonucleotide sequences were checked by
the Basic Local Alignment Search Tool against the GenBank
database for in silico speciﬁcity. Sequences were also checked
against alignments of all target gene sequences deposited in
GenBank for the species of interest to check in silico sensitivity.
On the basis of these assessments, eight targets were selected
for pathogen detection, with four targets per mRT-PCR assay.
The composition of each mRT-PCR assay is detailed in Table 2.
Discrimination of each target in the reaction was achieved with
the use of oligonucleotide probes labelled with one of four
ﬂuorophores: 6-FAM, Texas Red, Yakima Yellow, and Cy5. In
order to assess the quality of LRT specimens, a real-time
quantitative PCR assay was also designed with Beacon
Designer (Premier Biosoft) and the RefSeq gene NG_007073.2
for the detection of the human glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) gene. An already validated in-house
real-time PCR assay for the PhHV gB gene was used to
detect PCR inhibition [15].
Real-time PCR
Reactions were carried out on the ABI 7500 Fast instrument
(Applied Biosystems, Paisley, UK). mRT-PCR assays were car-
ried out in a total volume of 20 μL, comprising 10 μL of
QuantiFast Multiplex PCR mastermix (Qiagen), 2 μL of
nuclease-free water (Promega), 2 μL of oligonucleotide mixture
(Table 2), and 6 μL of nucleic acid extract. Cycle parameters
were 95°C for 5 min, followed by 45 cycles of 95°C for 45 s
and 60°C for 45 s. GAPDH real-time PCR was carried out with
the same reaction components, but with different cycle pa-
rameters: 95°C for 5 min, followed by 45 cycles of 95°C for
30 s and 60°C for 30 s. PhHV PCR was carried out with 10 μL
of Express qPCR Universal SuperMix (Invitrogen, Paisley, UK),
1 μL of oligonucleotide mixture (Table 2), and 9 μL of nucleicropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 788.e1–788.e13
nses/by-nc-nd/4.0/)
TABLE 2. Oligonucleotide sequences
Assay Organism Gene target Oligonucleotide
Final reaction
concentration
(μM) Reference
mRT-PCR 1 Streptococcus pneumoniae Autolysin (lytA) Forward: ACGCAATCTAGCAGATGAAGCA 0.10 [17]
Reverse: TCGTGCGTTTTAATTCCAGCT 0.10
Probe: YY-TGCCGAAAACGCTTGATACAGGGAG-BHQ1 0.05
Haemophilus inﬂuenzae L-Fuculokinase (fucK) Forward: ATGGCGGGAACATCAATGA 0.15 [20]
Reverse: ACGCATAGGAGGGAAATGGTT 0.15
Probe: FAM-CGGTAATTGGGATCCAT-MGB 0.10
Staphylococcus aureus Thermostable nuclease (nuc) Forward: AGCATCCTAAAAAAGGTGTAGAGA 0.15 [22]
Reverse: CTTCAATTTTMTTTGCATTTTCTACCA 0.15
Probe: TEX-TTTTCGTAAATGCACTTGCTTCAGGACCA-BHQ2 0.10
Moraxella catarrhalisa Outer membrane
protein (copB)
Forward: CGTGTTGACCGTTTTGACTTT 0.15 Modiﬁed from [23]
Reverse: CATAGATTAGGTTACCGCTGACG 0.15
Probe: Cy5-ACCGACATCAACCCAAGCTTTGG–BHQ3a 0.10
mRT-PCR 2 Escherichia colib Conserved protein,
function unknown (yccT)
Forward: ATCGTGACCACCTTGATT 0.25 Modiﬁed from [24]
Reverse: TACCAGAAGATCGACATC 0.25
Probe: TEX-CATTATGTTTGCCGGTATCCGTTT-BHQ2 0.10
Klebsiella pneumoniae Citrate synthase (gltA) Forward: AGGCCGAATATGACGAAT 0.25 Modiﬁed from [24]
Probe: this
publication
Reverse: GGTGATCTGCTCATGAA 0.25
Probe: YY-ACTACCGTCACCCGCCACA-BHQ1 0.10
Pseudomonas aeruginosa DNA gyrase subunit B (gyrB) Forward: CCTGACCATCCGTCGCCACAAC 0.25 [25]
Reverse: CGCAGCAGGATGCCGACGCC 0.25
Probe: FAM-CCGTGGTGGTAGACCTGTTCCCAGACC-BHQ1 0.10
Acinetobacter baumannii OXA-51-like β-lactamase
(blaOXA-51-like)
Forward: TTTAGCTCGTCGTATTGGACT 0.125 Modiﬁed from [28]
Reverse: CCTCTTGCTGAGGAGTAATTTT 0.125
Probe: Cy5-TGGCAATGCAGATATCGGTACCCA-BHQ3a 0.05
Specimen quality
control
Human Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH)
Forward: TTGTCTCACTTGTTCTCT 0.30 This publication
Reverse: ATGGGAGTTGTTTTCTTG 0.30
Probe: FAM-CTCGTCTTCTGTCATCTCTGCTG-BHQ1 0.20
Internal control
for inhibition
PhHV Glycoprotein B (gB) Forward: GGGCGAATCACAGATTGAATC 0.30 [15]
Reverse: GCGGTTCCAAACGTACCAA 0.30
Probe:Cy5-TTTTTATGTGTCCGCCACCATCTGGATC–BHQ3a 0.10
Fluorophores: BHQ, Black Hole Quencher; TEX, Texas Red; YY, Yakima Yellow.
mRT-PCR, multiplex real-time PCR; PhHV, phocine herpes virus.
aMoraxella catarrhalis assay detects Moraxella lacunata and Moraxella nonliquefaciens.
bEscherichia coli assay detects Shigella species.
CMI Gadsby et al. Quantitative PCR for eight respiratory bacterial pathogens 788.e4acid extract. Cycle parameters were 95°C for 20 s, followed by
45 cycles of 95°C for 3 s and 60°C for 30 s. Runs were
accepted if negative (no template) controls were negative and
positive controls for each ampliﬁcation target were positive.
For quantiﬁcation, mixed plasmid dilution series ranging from
6 × 101 to 6 × 106 gene copies/reaction were included in each
run. ABI 7500 Fast System SDS software v. 1.4 (Applied Bio-
systems) was used to construct a six-point standard curve and
extrapolate a quantitative result. Runs were accepted if stan-
dard curves were linear (reaction efﬁciency of 90–119%,
R2 > 0.98). Clinical specimens were classiﬁed as positive and
quantiﬁable for a bacterial target if the bacterial load was
100 CFUs/reaction. Quantitative results were accepted if the
internal control was positive with a quantiﬁcation cycle (Cq)
value within the range ±1 log (Cq ± 3.33) difference from
negative extraction controls. CFUs/reaction were assumed to
be equivalent to gene copies/reaction, because all of the bac-
terial target genes are single copy. Conversion of gene copies/
reaction to CFUs/mL was based on a 6-μL input per PCR re-
action drawn from 100 μL of nucleic acid extract concentrated
from 200 μL of specimen.
Analytical performance
PCR efﬁciency (E = 10(−1/slope) – 1) was estimated by testing at
least ten replicates of ten-fold mixed plasmid dilution series inClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of Eu
This is an open access artidifferent runs, andwas acceptable between the values of 0.90 and
1.10. The quantitative range was determined from the range of
ten-fold mixed plasmid dilutions that gave optimal linearity, ef-
ﬁciency, standard deviation and coefﬁcient of variation between
replicates. Analytical speciﬁcity was measured by testing DNA
extracted from the large panel of positive and negative control
isolates detailed above. Analytical sensitivity was estimated with
surplus anonymized sputum specimens spiked before extraction
with target bacterial species (mock specimens). These were
tested at ﬁve different bacterial spike concentrations in triplicate
per run, for four runs. A probit analysis was carried out to es-
timate the limit of detection of each assay (Minitab v.17). Preci-
sion by repeatability was used as a proxy for analytical accuracy,
as reference standards for quantiﬁcation of the eight bacterial
pathogens are not available. To encompass between-run and
within-run variation in both the extraction process and the PCR
process, mock specimens at three different bacterial spike con-
centrations were tested in triplicate per run, for four runs on
different days, with the same operator and equipment. To assess
performance in quantiﬁcation of mixed infections, plasmids were
mixed to give unequal mixtures for three targets at 200 000,
20 000 and 200 gene copies/reaction. This was carried out for
every combination of the four targets for both the mRT-PCR 1
assay and the mRT-PCR 2 assay (Table 3).ropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 788.e1–788.e13
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
TABLE 3. Matrix for triple mixture composition
Mixture
200 gene
Copies/reaction
20 000 gene
copies/reaction
200 000 gene
copies/reaction
1 A B C
2 A B D
3 A C D
4 A D C
5 A C B
6 A D B
7 B A C
8 B A D
9 B C D
10 B D C
11 B C A
12 B D A
13 C A B
14 C A D
15 C B D
16 C D B
17 C B A
18 C D A
19 D A B
20 D A C
21 D B C
22 D C B
23 D B A
24 D C A
For multiplex real-time PCR (mRT-PCR) 1: A = Streptococcus pneumoniae; B =
Haemophilus inﬂuenzae; C = Staphylococcus aureus; D = Moraxella catarrhalis.
For mRT-PCR 2: A = Escherichia coli; B = Klebsiella pneumoniae; C = Pseudomonas
aeruginosa; D = Acinetobacter baumannii.
788.e5 Clinical Microbiology and Infection, Volume 21 Number 8, August 2015 CMIPerformance on clinical LRT specimens
Anonymized residual sputum specimens from patients with
radiologically conﬁrmed pneumonia and bronchalveolar lavage
(BAL) ﬂuid specimens from critical-care patients were collected
between September 2012 and March 2015 following routine
microbiological culture. For sputum specimens, a ﬂeck of pus
was inoculated directly onto Columbia horse blood agar and
chocolate blood bacitracin agar (Oxoid, Basingstoke, UK),
spread for the production of discrete colonies, and incubated
for 48 h at 37°C in 5% CO2; microscopy was not carried out.
Isolates were identiﬁed with standard biochemical methods
and/or matrix-assisted laser desorption ionization time-of-ﬂight
mass spectrometry. Results for sputum specimens were re-
ported semiquantitatively in the following format: small
numbers—colonies present in the well of the plate only;
moderate numbers—colonies present in the ﬁrst streak out
from the well; and large numbers—colonies present in the
second or third streak out from the well. Microbiological cul-
ture of BAL ﬂuid specimens was carried out as for sputum
specimens, with the exception that cultures were quantitative;
plates were inoculated evenly with 10 μL of ﬂuid, and results
were reported as CFUs/mL. Residual specimens were stored at
–80°C before being tested retrospectively for this study.
Testing was carried out in accordance with local ethical
approval (South East Scotland SAHSC Human Annotated Bio-
Resource reference No. 10/S1402/33). Datasets were sub-
jected to a normality test, and differences between non-
parametric data were tested for signiﬁcance with the Mann–
Whitney test (Minitab v.17).Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of Eu
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceResultsAssay design
The eight bacterial pathogens chosen for the mRT-PCR 1 and
mRT-PCR 2 assays were the species most commonly detected
by conventional culture-based methods in patients with pneu-
monia in a recent local study [2]. Assay development and vali-
dation were carried out according to recent guidance [16]. The
lytA target was chosen for S. pneumoniae because it is well
characterized, sensitive and speciﬁc for the identiﬁcation of
S. pneumoniae, and superior to other targets, such as ply
[17,18]. The commonly used protein D-encoding gene hpd#3
assay target for H. inﬂuenzae was not employed in this study,
owing to the known cross-reaction with Haemophilus aphro-
philus [19]. The fucK target was chosen instead, because it had
similar sensitivity for the detection of H. inﬂuenzae and
discrimination from Haemophilus haemolyticus, and also per-
formed slightly better than hpd#3 in a recent reference
laboratory-based study [20,21]. The nuc target was chosen for
Staphylococcus aureus detection because it has also been well
evaluated in a reference laboratory setting [22]. Use of the copB
gene target is widespread for the detection of M. catarrhalis, but
some assays have primer mismatches with published
M. catarrhalis copB sequences, so an assay in a more conserved
region of the gene was chosen [23]. For the detection of E. coli
and K. pneumoniae, assays targeting yccT and gltA, respectively,
were used [24]. Owing to the high level of homology between
E. coli and Shigella species, it was not possible to ﬁnd an E. coli-
speciﬁc assay target. However, as Shigella species are very un-
likely to be found in the respiratory tract, this was not deemed
to be clinically relevant in the context of LRTI diagnosis. The
gyrB target was chosen for the detection of P. aeruginosa rather
than the commonly used ecfX target, because of its slightly
higher detection rate and speciﬁcity on clinical isolates [25–27].
The blaOXA-51-like gene chosen for A. baumannii detection has
been found in A. baumannii isolates, with a few exceptions, and
has not been detected in other Acinetobacter species [28–30].
Estimation of PCR efﬁciency, linearity, and quantitative
range
Ampliﬁcation was linear and efﬁcient for all targets within the
quantitative range 60–6 000 000 gene copies/reaction, with the
exception of the gyrB target, which had a quantitative range of
600–6 000 000 gene copies/reaction (Table 4). Within this
range, all replicates tested were positive, with Cq value stan-
dard deviations of 0.34–2.29 and coefﬁcients of variation of
1.68–8.85% for all targets. Outside the quantitative range, as-
says were non-linear and less efﬁcient, and low-concentration
replicates were not consistently detected.ropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 788.e1–788.e13
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This is an open access artiAnalytical sensitivity
Analytical sensitivity and limit of detection were estimated with
nine to 12 replicates of sputum specimens spiked with bacteria
at ﬁve different concentrations, from 1 to 100 000 CFUs/re-
action (Table 4). Both the mRT-PCR 1 assay and the mRT-PCR
2 assay were highly sensitive for the detection of all bacteria in
mock specimens down to the level of 100 CFUs/reaction,
except for P. aeruginosa, for which the assays were approxi-
mately 1 log less sensitive. Limits of detection were approxi-
mately 1–100 CFUs/reaction (corresponding to
83–8333 CFUs/mL), depending on the target.
Analytical speciﬁcity
Coverage of a large panel of control isolates was 100% for all
assay targets, and there were no cross-reactions between tar-
gets within the mRT-PCR 1 assay and the mRT-PCR 2 assay.
Speciﬁcity against a panel of 88 isolates closely related to the
target organisms and/or commonly found in the respiratory
tract as pathogens or commensals was 100% for all targets, with
the exception of copB, which was 98% speciﬁc, owing to cross-
reactivity with Moraxella lacunata and Moraxella nonliquefaciens
(Tables 5 and 6). However, the copB assay did not detect
Moraxella osloensis or Moraxella atlantae.
Precision (repeatability)
Precision was measured by comparing bacterial load quantiﬁca-
tion by the mRT-PCR 1 assay and the mRT-PCR 2 assay for
11–12 replicates of PCR-negative sputum specimens spiked with
each of the eight target bacteria at high (100 000 CFUs/reaction),
medium (1000 CFUs/reaction) and low (100 CFUs/reaction)
concentrations. The numbers of replicates with bacterial load
quantiﬁed within a 1 log CFUs/reaction range for high, medium
and low target concentrations were 96 of 96 (100%), 89 of 96
(92.7%), and 86 of 92 (93.5%), respectively. The most precise
assays were for S. pneumoniae and H. inﬂuenzae, because all
replicates were within a 1 log CFUs/reaction range. The least
precise assays were for Staphylococcus aureus, M. catarrhalis, and
P. aeruginosa; these quantiﬁed 33 of 36 (91.7%), 32 of 36 (88.9%)
and 32 of 35 (91.4%) replicates, respectively, within the 1 log
range. Overall, the results indicated that reliable bacterial load
quantiﬁcation from sputum specimens was achievable with both
assays down to a concentration of 100 CFUs/reaction, which is
equivalent to 8333 CFUs/mL.
Detection of targets in unequal triple mixtures
The Cq value for each target in a mixture was similar to the
Cq value for that target alone, and all values were tightly
clustered, with standard deviations within the range 0.14–1.10
(Fig. 1). Therefore, all components within a triple mixture,
including the minority component, could be accuratelyropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 788.e1–788.e13
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
TABLE 5. Analytical speciﬁcity summary for multiplex real-time PCR 1 detection (no. (%))
Isolates Streptococcus pneumoniae Haemophilus inﬂuenzae Staphylococcus aureus Moraxella catarrhalis
Streptococcus pneumoniae 36/36 (100) 0/36 (0) 0/36 (0) 0/36 (0)
Haemophilus inﬂuenzae 0/47 (0) 47/47 (100) 0/47 (0) 0/47 (0)
Staphylococcus aureus 0/41 (0) 0/41 (0) 41/41 (100) 0/41 (0)
Moraxella catarrhalis 0/26 (0) 0/26 (0) 0/26 (0) 26/26 (100)
Panel of 88 respiratory and related
organisms + Escherichia coli, Klebsiella
pneumoniae, Pseudomonas aeruginosa,
and Acinetobacter baumannii
0/92 (0) 0/92 (0) 0/92 (0) 2/92a (2)
aMoraxella lacunata and Moraxella nonliquefaciens were copB positive.
TABLE 6. Analytical speciﬁcity summary for multiplex real-time PCR 2 detection (no. (%))
Isolates Escherichia coli Klebsiella pneumoniae Pseudomonas aeruginosa Acinetobacter baumannii
Escherichia coli 28/28 (100) 0/28 (0) 0/28 (0) 0/28 (0)
Klebsiella pneumoniae 0/28 (0) 28/28 (100) 0/28 (0) 0/28 (0)
Pseudomonas aeruginosa 0/26 (0) 0/26 (0) 26/26 (100) 0/26 (0)
Acinetobacter baumannii 0/17 (0) 0/17 (0) 0/17 (0) 17/17 (100)
Panel of 88 respiratory and related organisms + Streptococcus
pneumoniae, Haemophilus inﬂuenzae, Staphylococcus aureus
and Moraxella catarrhalis
0/92 (0) 0/92 (0) 0/92 (0) 0/92 (0)
788.e7 Clinical Microbiology and Infection, Volume 21 Number 8, August 2015 CMIquantiﬁed despite the presence of other components at
different concentrations.
Testing of clinical specimens
Twenty consecutive culture-negative sputum specimens ob-
tained from individual patients with pneumonia were retro-
spectively tested with the novel assays. Specimens had a median
GAPDH concentration of 139 659 gene copies/reaction (range:
10 853–1 030 000 gene copies/reaction). Twelve of 20 (65%)
specimens were positive with the mRT-PCR 1 and mRT-PCR 2
assays, with seven (58.3%) single infections and ﬁve (41.7%)
mixed infections (Table 7). In addition, a further 20 consecutive
sputum specimens, culture positive for any of the eight bacterial
pathogens targeted by the mRT-PCR 1 and mRT-PCR 2 assays,
were retrospectively tested with the novel assays. These
specimens had a median GAPDH concentration of 134 000 gene
copies/reaction (range: 4876–729 000 gene copies/reaction),
which was not signiﬁcantly different from that in the culture-
negative group (p 0.968). In 20 of 20 (100%) sputum speci-
mens, the mRT-PCR 1 and mRT-PCR 2 assays detected the
same bacterial species grown in culture (Table 7). Furthermore,
the novel PCR assays detected an additional 15 bacterial in-
fections, giving a total of 11 (55%) single infections and nine
(45%) mixed infections. By semiquantitative sputum culture, the
majority of isolates present were reported as large numbers of
organisms, corresponding to between 4.68 × 104 CFUs/mL and
1.10 × 1010 CFUs/mL as measured by the mRT-PCR assay
(Table 7). However, bacterial loads were signiﬁcantly lower inClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of Eu
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licethe culture-negative group (median: 3.50 × 105 CFUs/mL) than
in the culture-positive group (median: 3.33 × 108 CFUs/mL) (p
0.0001) (Fig. 2). Finally, 20 consecutive BAL ﬂuid specimens
obtained from individual patients admitted to critical care were
retrospectively tested with the novel assays (Table 7). GAPDH
was quantiﬁed in 18 of 20 BAL ﬂuid specimens, and this gave a
median GAPDH concentration of 24 720 gene copies/reaction
(range: 892–176 356 gene copies/reaction), which was signiﬁ-
cantly lower than in sputum specimens (p 0.0006). Concordant
results for bacterial targets in the mRT-PCR assays were ach-
ieved for 18 of 20 specimens, with seven additional bacterial
infections being identiﬁed by PCR. Two specimens gave
discordant results for bacterial targets present in the mRT-PCR
assays: one specimen grew 3.0 × 102 CFUs/mL of S. aureus and
was PCR negative; a second specimen grew 1.0 × 104 CFUs/mL
of K. pneumoniae and was K. pneumoniae PCR negative at just
below the 100 CFUs/reaction cut-off for the assay. When
culture-positive specimens were detected by the mRT-PCR
assays, quantitative PCR bacterial loads were in the same or-
der of magnitude as or higher than those of quantitative culture
(Table 7). Candida species and Morganella morganii were iden-
tiﬁed in ﬁve specimens, but targets for these organisms were
not present in the PCR assays. In three specimens, overgrowth
of respiratory ﬂora is likely to have masked the existence of
respiratory pathogens; culture results were reported as ‘no
signiﬁcant growth’ or ‘upper respiratory tract ﬂora’, but the
mRT-PCR assays identiﬁed >104 CFUs/mL of at least one
pathogen.ropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 788.e1–788.e13
nses/by-nc-nd/4.0/)
FIG. 1. Distribution of Cq values in triple unequal mixture (n = 6) and single (n = 1) plasmid positive control material for each assay target at three
concentrations (200, 20 000 and 200 000 gene copies/reaction).
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TABLE 7. Bacterial detection by multiplex real-time PCR (mRT-PCR) 1 and mRT-PCR 2 assays in lower respiratory tract
specimens (sputa, n [ 40; bronchoalveolar lavage (BAL), n [ 20)
Specimen type (no. of specimens) Standard culture mRT-PCR 1 and mRT-PCR 2 result
Sputum No growth Haemophilus inﬂuenzae 2.81 × 106 CFUs/mL
Sputum No growth H. inﬂuenzae 5.56 × 105 CFUs/mL
Sputum No growth H. inﬂuenzae 6.31 × 107 CFUs/mL
Sputum No growth H. inﬂuenzae 3.43 × 105 CFUs/mL
Sputum No growth Streptococcus pneumoniae 3.87 × 107 CFUs/mL
Sputum No growth S. pneumoniae 4.26 × 107 CFUs/mL
Sputum No growth Escherichia coli 1.91 × 105 CFUs/mL
Sputum No growth H. inﬂuenzae 1.47 × 108 CFUs/mL
S. pneumoniae 1.99 × 104 CFUs/mL
Sputum No growth H. inﬂuenzae 8.42 × 106 CFUs/mL
Moraxella catarrhalis 1.46 × 104 CFUs/mL
Sputum No growth H. inﬂuenzae 3.50 × 105 CFUs/mL
E. coli 4.18 × 104 CFUs/mL
Sputum No growth H. inﬂuenzae 9.76 × 103 CFUs/mL
S. pneumoniae 1.43 × 106 CFUs/mL
M. catarrhalis 8.74 × 103 CFUs/mL
Sputum No growth S. pneumoniae 1.12 × 107 CFUs/mL
E. coli 3.11 × 104 CFUs/mL
Sputum (eight specimens) No growth Negative
Sputum H. inﬂuenzae (LN) H. inﬂuenzae 2.52 × 109 CFUs/mL
Sputum H. inﬂuenzae (LN) H. inﬂuenzae 1.14 × 109 CFUs/mL
Sputum H. inﬂuenzae (LN) H. inﬂuenzae 4.06 × 108 CFUs/mL
Sputum H. inﬂuenzae (LN) H. inﬂuenzae 5.48 × 108 CFUs/mL
Sputum H. inﬂuenzae (LN) H. inﬂuenzae 5.10 × 109 CFUs/mL
Sputum H. inﬂuenzae (LN) H. inﬂuenzae 3.24 × 108 CFUs/mL
Sputum H. inﬂuenzae (SN) H. inﬂuenzae 2.49 × 108 CFUs/mL
S. pneumoniae 2.47 × 106 CFUs/mL
Sputum H. inﬂuenzae (LN) H. inﬂuenzae 3.41 × 108 CFUs/mL
S. pneumoniae 1.58 × 108 CFUs/mL
Sputum H. inﬂuenzae (LN) H. inﬂuenzae 1.10 × 1010 CFUs/mL
M. catarrhalis 2.22 × 104 CFUs/mL
Sputum H. inﬂuenzae (LN) H. inﬂuenzae 4.68 × 104 CFUs/mL
M. catarrhalis 9.42 × 106 CFUs/mL
Sputum H. inﬂuenzae (LN) H. inﬂuenzae 1.77 × 109 CFUs/mL
S. pneumoniae 3.79 × 104 CFUs/mL
M. catarrhalis 2.45 × 104 CFUs/mL
Staphylococcus aureus 3.49 × 104 CFUs/mL
Sputum S. pneumoniae (LN) S. pneumoniae 8.67 × 108 CFUs/mL
Sputum S. pneumoniae (LN) S. pneumoniae 1.65 × 107 CFUs/mL
H. inﬂuenzae 9.42 × 103 CFUs/mL
M. catarrhalis 4.43 × 104 CFUs/mL
Sputum S. pneumoniae (LN) S. pneumoniae 1.12 × 105 CFUs/mL
H. inﬂuenzae 6.28 × 108 CFUs/mL
M. catarrhalis 1.42 × 107 CFUs/mL
E. coli 2.95 × 106 CFUs/mL
Klebsiella pneumoniae 2.36 × 105 CFUs/mL
Sputum E. coli (LN) E. coli 8.92 × 108 CFUs/mL
Sputum E. coli (LN) E. coli 1.17 × 105 CFUs/mL
S. pneumoniae 1.42 × 104 CFUs/mL
Sputum Pseudomonas aeruginosa (MN) P. aeruginosa 8.27 × 104 CFUs/mL
Sputum P. aeruginosa (LN) P. aeruginosa 6.02 × 106 CFUs/mL
S. pneumoniae 1.97 × 107 CFUs/mL
Sputum M. catarrhalis (LN) M. catarrhalis 2.40 × 108 CFUs/mL
Sputum Staphylococcus aureus (MN) Staphylococcus aureus 1.59 × 107 CFUs/mL
BAL (seven specimens) No growth Negative
BAL No growth H. inﬂuenzae 9.71 × 103 CFUs/mL
BAL No signiﬁcant growth H. inﬂuenzae 5.07 × 106 CFUs/mL
BAL No signiﬁcant growth E. coli 1.29 × 105 CFUs/mL
Staphylococcus aureus 1.85 × 104 CFUs/mL
BAL Upper respiratory tract ﬂora
Candida albicans 2 × 102 CFUs/mL
S. pneumoniae 4.30 × 105 CFUs/mL
BAL Candida albicans 7 × 103 CFUs/mL Negative
BAL Candida glabrata Negative
BAL Morganella morganii 1 × 104 CFUs/mL Negative
BAL E. coli 2 × 103 CFUs/mL
S. pneumoniae 1 × 104 CFUs/mL
H. inﬂuenzae 1 × 104 CFUs/mL
E. coli 3.31 × 105 CFUs/mL
S. pneumoniae 2.90 × 106 CFUs/mL
H. inﬂuenzae 6.21 × 107 CFUs/mL
BAL P. aeruginosa >1 × 104 CFUs/mL P. aeruginosa 2.21 × 105 CFUs/mL
BAL E. coli >1 × 104 CFUs/mL E. coli 1.48 × 108 CFUs/mL
(M. catarrhalis target just below cut-off)
BAL E. coli 3 × 102 CFUs/mL
Candida tropicalis >1 × 104 CFUs/mL
E. coli 8.38 × 105 CFUs/mL
H. inﬂuenzae 3.26 × 105 CFUs/mL
BAL Staphylococcus aureus 3 × 102 CFUs/mL Negative
BAL K. pneumoniae 1 × 104 CFUs/mL Staphylococcus aureus 5.71 × 104 CFUs/mL
(K. pneumoniae target just below cut-off)
LN, large numbers; MN, moderate numbers; SN, small numbers.
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FIG. 2. Bacterial loads calculated by
multiplex real-time PCR (mRT-PCR) in
culture-positive (n = 20) and culture-
negative (n = 20) sputum specimens
from patients with pneumonia. Ab, Acine-
tobacter baumannii; Ec, Escherichia coli; Hi,
Haemophilus inﬂuenzae; Kp, Klebsiella
pneumoniae; Mc, Moraxella catarrhalis; Pa,
Pseudomonas aeruginosa; Sa, Staphylococcus
aureus; Sp, Streptococcus pneumoniae.
CMI Gadsby et al. Quantitative PCR for eight respiratory bacterial pathogens 788.e10DiscussionWe have described the development and validation of two
quantitative mRT-PCR assays for eight important respiratory
bacterial pathogens, and demonstrated their potential as an
improved diagnostic tool in LRTI. Through in silico analysis and
in vitro experimentation, we have designed assays that sensi-
tively and speciﬁcally detect the targeted bacterial species.
Bacterial targets could be reliably quantiﬁed from sputum
specimens down to a concentration of 100 CFUs/reaction or
approximately 8000 CFUs/mL.
A key strength of our study was that all 249 positive control
isolates were correctly detected with our assay, demonstrating
its effectiveness on both reference strains and local clinical
isolates. Concordance with culture for 20 culture-positive
sputum specimens was also 100%. In addition, speciﬁcity on a
panel of nearly 100 negative control isolates was 98%.
Furthermore, the two assays quantiﬁed bacterial load accu-
rately when three bacterial targets were present in mixtures of
varying concentrations, mimicking likely clinical scenarios in
LRTI. These assays are combined with controls for specimen
quality and reaction inhibition, and run on a standard fast real-
time PCR platform, enabling results to be produced within 6 h
of specimen receipt. To the best of our knowledge, there are
no other quantitative molecular assays for LRTI diagnosis that
have been as extensively validated and meet these criteria.
One of the weaknesses of our study was that an extended
extraction protocol was required before processing on an
automated platform, increasing manual complexity and turn-
around time. This was necessary for efﬁcient extraction of
Staphylococcus aureus DNA from sputum specimens, as we had
previously found that mock specimens containing Staphylococcus
aureus spikes were underquantiﬁed with standard automatedClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of Eu
This is an open access artiextraction only. Enzymatic lysis of Staphylococcus aureus with
achromopeptidase has been described as both rapid and efﬁ-
cient, and therefore warrants further investigation as an alter-
native method in this setting [31]. However, when particularly
mucopurulent specimens, such as sputa, are used, an additional
proteinase K incubation step may still be required, in order to
fully break down the material before addition to an automated
extraction system. Despite the limitations of the current pro-
tocol, results are achievable in 6 h, owing to the use of auto-
mated systems and fast mRT-PCR, thus enabling same-day
reporting for specimens received in the morning. This is still
quicker than culturing even the faster-growing Gram-negative
pathogens in our panel, and means that a comprehensive multi-
pathogen result is available at a single time-point.
We set criteria for acceptance of quantiﬁcation results based
on the Cq of the internal control falling within a 1 log range;
outside of this range, quantitative results were not accepted,
owing to the potential for partial PCR inhibition leading to in-
accuracy of measurement. However, as our quantitative mRT-
PCR and internal control assays utilize different reagents, they
may not be equally affected by the presence of PCR inhibitors,
and therefore a bacterial load output from an assay meeting the
quality control criteria could still potentially be an underesti-
mate. This was not an issue during the sputum bacterial spiking
experiments carried out here, although these were limited in
number. Similarly, testing of BAL ﬂuid specimens showed that
quantitative PCR bacterial loads were generally higher than
those obtained with quantitative culture, but BAL ﬂuid is
signiﬁcantly less cellular than sputum, and would therefore be
expected to be less inhibitory.
Furthermore, we tested only a small number of sputum and
BAL specimens for comparison with culture in a proof-of-
principle experiment. However, this demonstrated the poten-
tial clinical utility of our molecular assays and the suitability ofropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 788.e1–788.e13
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
788.e11 Clinical Microbiology and Infection, Volume 21 Number 8, August 2015 CMIthese two contrasting LRT specimen types. It was clear from
our small collection of clinical specimens that there is an added
beneﬁt with mRT-PCR; it can detect more bacterial infections
than culture alone, and provide a simultaneous quantitative
output. Specimens that were culture positive for any of the
eight bacterial pathogens targeted by the mRT-PCR assays had
higher bacterial loads than those that were culture negative,
indicating the increased sensitivity of PCR as compared with
culture. This may prove to be particularly useful in the hospital
setting, where patients are more likely to have prior antibiotic
exposure before specimens are taken, thus reducing bacterial
burden and viability.
A signiﬁcant issue that we discovered during development
was that the copB assay for M. catarrhalis cross-reacted with
M. nonliquefaciens and M. lacunata isolates. Although several
other authors have used assays based on the copB gene to
target M. catarrhalis [23,32–34], none have reported its speci-
ﬁcity against M. nonliquefaciens, and only one study tested
M. lacunata, with no cross-reactivity being detected [32]. In silico
analysis did not predict copB cross-reactions, because of a lack
of genomic sequence data and copB gene sequences for Mor-
axella species in GenBank. M. nonliquefaciens andM. lacunata are
members of the normal respiratory microbiota, but rarely
cause respiratory tract infection themselves [35]. The paucity of
sequence data makes design of a more speciﬁc M. catarrhalis
assay problematic, and therefore the clinical relevance of this
cross-reaction is uncertain at present. However, the ﬂexibility
of an in-house mRT-PCR format means that, once further
sequence information is available, a modiﬁed M. catarrhalis assay
could be readily incorporated and revalidated. In the meantime,
we recommend that other groups who currently use the copB
gene target for M. catarrhalis be aware of the potential for
cross-reactivity with some Moraxella species when reporting
results from direct detection on respiratory specimens.
Furthermore, as the copB assay did not cross-react with
M. osloensis or M. atlantae, this assay cannot be regarded as a
genus-speciﬁc Moraxella species assay. Cross-reactivity is also
an issue for E. coli PCR assays, owing to the high level of ho-
mology between E. coli and Shigella species. However, as Shigella
species are very unlikely to be found in the respiratory tract,
this is unlikely to be diagnostically relevant in a respiratory
context.
In order to enable accurate molecular diagnosis of LRTI, a
specimen should ideally be: (a) obtained from the LRT rather
than the upper respiratory tract (URT); and (b) of good quality,
i.e. purulent material rather than salivary in the case of sputum.
This is because of the potential for detection of colonization
rather than infection when URT specimens are used, and the
potential for contamination of LRT specimens with oral ﬂora
during sampling. For this reason, our assays have beenClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of Eu
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licedeveloped for use on sputum and BAL ﬂuid specimens rather
than throat swabs or nasopharyngeal aspirates, and have an in-
built measure of cellular content for quality control (GAPDH).
Microscopy can be carried out to determine the quality of a
sputum specimen based on the numbers of polymorphonuclear
leukocytes and squamous epithelial cells [1], but GAPDH is
present in all cells, and therefore does not allow such
discrimination. Sputum microscopy is not routinely carried out
in our centre, so we do not know to what extent our cellular
load outputs were likely to be inﬂuenced by contaminating
epithelial cells from the URT, but we deliberately used only
macroscopically purulent material from sputum specimens for
PCR in this study for a direct comparison with culture.
Rates of URT asymptomatic carriage of S. pneumoniae and
H. inﬂuenzae in adults have been studied most frequently by
PCR, and range from 2% and 39%, depending on the setting
[36,37]. Furthermore, molecular studies using paired specimens
have shown that the bacteria and viruses detected in the URT
may not accurately reﬂect the organisms detected in the LRT
[38–40]. However, quantiﬁcation of bacterial DNA load may
be important in distinguishing infection from asymptomatic
colonization; most work described to date has focused on
S. pneumoniae, and a cut-off of 104 to 105 gene copies/mL has
typically been described [3,41–43]. Therefore, our assay could
be used to investigate whether similar clinical cut-offs can be
determined for other respiratory bacteria and for conditions
other than pneumonia. In comparison with semiquantitative
sputum culture in patients with pneumonia, we found that,
although the majority of isolates were reported as ‘large
numbers’ of organisms in monomicrobial infections, a wide
range of CFUs/mL was measured by quantitative PCR and many
organisms were detected in mixed infections in different pro-
portions. In some cases, the organism grown in culture was not
the organism with the highest bacterial load in a polymicrobial
infection as determined by quantitative PCR. Overall, these
observations may indicate the tendency of one organism to
overgrow others in culture, leading to under-reporting of
mixed infections. Our assay could also be used in settings
where quantitative culture of respiratory specimens is the
norm and rapid diagnosis is of key importance. For example, the
use of quantitative culture for BAL ﬂuid is standard for the
microbiological diagnosis of ventilator-acquired pneumonia,
with a cut off of 104 CFUs/mL [44]. As proof-of-principle, we
were able to quantify bacterial loads in BAL ﬂuid specimens
from critical-care patients with comparable results to those
obtained with culture, and many of the major ventilator-
acquired pneumonia pathogens are included in our assay.
Therefore, the use of mRT-PCR assays could provide a faster
quantitative result in this setting. Although not validated for use
here, there is also scope to use our mRT-PCR assays on wholeropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 788.e1–788.e13
nses/by-nc-nd/4.0/)
CMI Gadsby et al. Quantitative PCR for eight respiratory bacterial pathogens 788.e12blood specimens, as higher DNA loads have been found to
correlate with disease severity in some studies [45–47].
In conclusion, a quantitative molecular test for the key
bacterial causes of LRTI has the potential to provide a more
sensitive decision-making tool, closer to the time-point of pa-
tient admission, than current standard methods. A faster and
more accurate microbiological diagnosis should facilitate de-
escalation from broad-spectrum to narrow-spectrum antibi-
otics, substantially improving patient management and sup-
porting efforts to curtail inappropriate antibiotic use.Transparency declarationThe authors have no conﬂicts of interest to declare for this
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